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MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression post-transcriptionally. They are involved
in almost all cellular processes, and many have been described as potential oncogenes or tumor suppressors.
MicroRNA-373 (miR-373), which was first identified as a human embryonic stem cell (ESC)-specific miRNA, is
suggested to be implicated in the regulation of cell proliferation, apoptosis, senescence, migration and invasion,
as well as DNA damage repair following hypoxia stress. Deregulation of miR-373 has been demonstrated in a
number of cancers, whether it acts as an oncogene or a tumor suppressor, however, seems to be context
dependent. In this review, we focus on the diverse functions of miR-373 and its implication in cancers.
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MicroRNAs (miRNAs) are small noncoding RNAs ap-
proximately 22 nucleotides (nt) in length that are engaged
in virtually all cellular processes [1, 2]. Generally, miRNAs
negatively regulate gene expression by repressing transla-
tion or inducing degradation of target messenger RNAs
(mRNAs). However, miRNAs can also positively regulate
gene expression by modulating promoter activity or
activating translation [3–5]. In mammals, miRNAs are
predicted to control the activity of ~50 % of all
protein-coding genes, and deregulated expression of
miRNAs has been implicated in a variety of human
diseases including cancer [2].
miRNA-373 (miR-373) was first identified as one of
the human embryonic stem cell (ESC)-specific miRNAs
[6]. Subsequently, it was validated as a potential novel
oncogene with the evidence that it can permit prolifera-
tion and tumorigenesis of primary human cells harbor-
ing both oncogenic RAS and active wild-type p53 [7].
From that time forth, the functions of miR-373 in
tumors as well as the potential targets of miR-373 have
been an interested research field. miR-373 has been
documented to suppress target mRNAs translation and/
or degrade target mRNAs [7–28], besides, it can also* Correspondence: wjf_1030@126.com
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of miR-373 has been demonstrated in a number of can-
cers, while indisputable evidence has demonstrated that
miR-373 is an oncogene [7, 8, 10, 11, 14, 15, 18–21, 32,
33], solid documents suggested its tumor suppressor
character [13, 16, 22–24, 27, 30, 31, 34, 35]. The focus of
this review is to highlight the diverse functions of miR-373
and its implication in cancer.Functions of miR-373
miR-373 is located in the chromosomal band 19q13.4. It
belongs to miR-371-3 gene cluster that is transcribed
into polycistronic primary transcript pri-miR-371-3. The
pri-miR-371-3 is then processed into 3 pre-miRNAs
(pre-miR371, pre-miR-372 and pre-miR-373), giving rise
to four mature miRNAs (miR-371, miR-372, miR-373
and miR-373*) [6, 7]. miR-373 is one member of
miR520/373 family, which consists of three different
miRNA clusters possessing identical seed region, miR-
302/367, miR-371/372/373 and miR-520 [8, 18, 22].
Therefore, when we discuss the functions of miR-373
here, we should bear in mind that other members of
miR-520/373 family may possess the same functions.
miR-373 orchestrates its functions either by pairing to
the 3’ untranslated regions (UTR) of specific mRNAs to
post-transcriptionally down-regulate gene expression, or
by binding to the promoters of target DNAs to up-
regulate gene expression. Numerous target mRNAs and
DNAs have been verified [4, 7–31], contributing to the
potential roles of miR-373 in cellular processes (Table 1).is is an Open Access article distributed under the terms of the Creative
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Table 1 Verified direct targets of miR-373
Gene Symbol Description Regulationa References
LATS2 large tumor tuppressor, homolog 2 ↓ [7, 10, 12, 21]
CD44 CD44 molecule ↓ [8, 11, 21]
CDH1 cadherin 1, type 1, E-cadherin ↑ [4, 29–31]
CSDC2 cold shock domain containing C2, RNA binding ↑ [4]
RAD52 Rad52 DNA Repair and Recombination Protein ↓ [9]
RAD23B RAD23 homolog B ↓ [9]
MBD2 methyl-CpG binding domain protein 2 ↓ [13]
NFIB nuclear factor I/B ↓ [17]
RAB22A RAB22A, member RAS oncogene family ↓ [16, 24]
PPP6C protein phosphatase 6, catalytic subunit ↓ [14]
TXNIP thioredoxin interacting protein ↓ [15]
RABEP1 rabaptin, RAB GTPase binding effector protein 1 ↓ [15]
RelA v-rel avian reticuloendotheliosis viral oncogene homolog A ↓ [22, 27]
TGFBR2 transforming growth factor-beta type II receptor ↓ [19, 22]
mTOR Mammalian Target of Rapamycin ↓ [18]
SIRT sirtuin (silent mating type information regulation 2 homolog) ↓ [18]
DKK1 dickkopf homolog 1 ↓ [19]
BTG1 B-cell translocation gene 1, anti-proliferative protein ↓ [19]
LEFTY1 left-right determination factor 1 ↓ [19]
TNFAIP1 tumor necrosis factor, alpha-induced protein 1 ↓ [20]
TP53INP1 tumor protein p53 inducible nuclear protein 1 ↓ [21]
IRAK2 interleukin-1 receptor-associated kinase 2 ↓ [23]
LAMP1 lysosomal-associated membrane protein 1 ↓ [23]
MMP14 matrix metallopeptidase 14 (membrane-inserted) ↓ [25]
ER estrogen receptor ↓ [26]
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha ↓ [27]
JAK1 Janus kinase 1 ↓ [28]
IRF9 interferon regulatory factor 9 ↓ [28]
aExpression regulation of target genes by miR-373: ↓ represents down-regulation, ↑ represents up-regulation
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regulation of cell proliferation [10, 14, 16, 19–21, 23, 33],
apoptosis [26, 27], senescence [7], mesendoderm differen-
tiation [36], migration and invasion [8, 11, 18, 19, 23–25,
30, 31], it was also involved in hypoxia response as a
hypoxia-induced miRNA, taking part in DNA damage re-
pair [9] (Fig. 1).
miR-373 regulates cell growth
Cellular senescence is a state of irreversible cell cycle ar-
rest, which limits the proliferative capacity of cells ex-
posed to stress signals. Oncogene activation can induce
cellular senescence, which stands as a natural barrier
against tumorigenesis [37, 38]. However, by inactivation
of tumor suppressors involved in senescence, such as
P53 and RB, transformed cells overcome this barrier and
reacquire proliferative capacity [39]. To identify miRNAswhich cooperate with oncogenic RAS to overcome onco-
gene induced senescence, Voorhoeve et al. [7] developed
a library of vectors expressing the majority of cloned
human miRNAs, and identified miR-372 as well as miR-
373 as an oncogene for the first time. While oncogenic
stress leads to activation of P53 and induction of P21,
which results in cell cycle arrest and senescence, the
introduction of miR-372 or miR-373 prevents the inhib-
ition of CDK by targeting tumor suppressor LATS2 dir-
ectly, thereby permitting proliferation and tumorigenesis
of transformed cells [7]. Subsequent investigations fur-
ther reinforce the oncogenic potential of miR-373. In
addition to LATS2 [10, 12, 21], many other tumor sup-
pressors such as PPP6C [14], DKK1 [19], TNFAIP1 [20]
and TP53INP1 [21] are also verified as direct targets of
miR-373, implying that miR-373 promotes cell prolifera-
tion and tumor growth under certain conditions.
Fig. 1 Regulation network of miR-373. Green boxes display upstream regulators of miR-373, black boxes contain representive functional targets of
miR-373, and blue boxes imply the correspondingly involved cellular processes. Upstream factors lead to altered expression of miR-373. miR-373
exerts its functions by suppressing or promoting multiple target genes expression, and is involved in regulation of cell proliferation and growth,
cell migration, invasion and metastasis, and DNA damage repair
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moting function of miR-373, a number of studies also
presented the tumor suppressive potential of miR-373.
miR-373 expression levels are down-regulated in a var-
iety of cancers, including cholangiocarcinoma [13], colon
cancer [16], pancreatic cancer [31], lung cancer [23] and
ovarian cancer [24], overexpression of miR-373 could in-
hibit cell proliferation and tumor growth. Mechanism
analysis revealed many putative oncogenes as the direct
target of miR-373, including MBD2 [13], RAB22A [16],
RelA and PIK3CA [27] (Table 1).
miR-373 modulates cell migration and invasion
Invasion and metastasis represent the aggressiveness of
cancer, predicting poor prognosis in patients. Exploring
the underlying mechanism of cell migration and invasion
is critical to improve our understanding of cancer me-
tastasis and discover potential therapeutic targets [40].
Recent researches suggest that miRNAs are a set of im-
portant molecular regulators modulating cell migration
and invasion [41–43].
miR-373 was first identified as a metastasis-promoting
miRNA in breast cancer. Using a forward genetic screen,
Huang et al. [8] transduced MCF-7 cells with a miRNA-
expression library and performed transwell cell migra-
tion assay to assess their migration ability, identified
miR-373 and miR-520c as metastasis-promoting miRNAs.
CD44 was determined as a functional target of miR-373
and miR-520c, down-regulation of CD44 by miR-373 was
responsible for the migration phenotype. Based on the
metastasis-promoting function of miR-373 in MCF-7
cells, Yan et al. [15] implemented a quantitative proteo-
mics to globally identify the genes regulated by miR-373.They evidenced that more than 30 proteins involved in
cancer invasion and metastasis were found to be regulated
by miR-373, among which TXNIP and RABEP1 were
demonstrated to be the direct targets. In human fibrosar-
oma HT1080 cells, miR-373 and miR-520c can also pro-
mote migration. By targeting mTOR and SIRT1 directly,
which are negative regulators of MMP9 expression, miR-
373 and miR-520c up-regulates the expression level of
MMP9, resulting in increased cell migration [18].
Paradoxically, miR-373 has been demonstrated to
function also as a suppressor of cell migration and inva-
sion. E-cadherin, a well-known regulator of migration
and invasion [44], can be up-regulated by miR-373 [4,
30, 31]. Overexpression of miR-373 in A549 cells in-
creased the expression level of E-cadherin, resulting in
decreased migration [30]. The Hepatitis B × antigen
(HBx), which is involved in HBV-related hepatocellular
carcinoma (HCC), was shown to be able to down-
regulate the expression miR-373 which correspondingly
reduces E-cadherin expression, suggesting that HCC with
low miR-373 expression level might be more invasive [29].
In addition to E-cadherin, TGFBR2 [22], RAB22A [24],
MMP14 [25], IRAK2 and LAMP1 [23] were also identified
as direct targets of miR-373 that contributing to its
metastasis-inhibiting function.
miR-373 takes part in hypoxic response
Hypoxia is a common feature of the tumor microenvir-
onment and has been recognized as a culprit that
confers hallmark capabilities to cancer cells [45]. Under
hypoxic stress, cancer cells switch to glycolytic metabol-
ism, develop self-sufficient growth signal, become resist-
ant to apoptosis, acquire unlimited replication potential
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duce angiogenesis and metastasis [46].
miRNAs have recently been shown to play an essential
role in the regulation of the cellular response to hypoxia,
which are termed as hypoxia-regulates miRNAs (HRMs)
or HypoxamiRs [47]. Among the identified HRMs, only
miR-210, the master HRM, shows consistent up-
regulation under hypoxia in all cell types, other HRMs,
including miR-373, response to hypoxia in a cell-specific
way [48]. In cervical cancer cell line HeLa and breast
cancer cell line MCF-7, miR-373 was up-regulated under
hypoxia [9]. However, no significant up-regulation of
miR-373 was detected in hypoxic prostate cancer cell
lines [49].
miR-373, up-regulated under hypoxic conditions in
certain cancer cells, has been demonstrated to play a
role in hypoxic response. By reducing the expression of
RAD52, which is an important factor in homology-
dependent repair, and RAD23B, which is involved in nu-
cleotide excision repair, miR-373 impairs the DNA dam-
age repair, thereby resulting in genetic instability [9].
Whether hypoxia-induced miR-373 could regulate hyp-
oxic cell growth or modulate hypoxic cell migration and
invasion deserves further investigations.
Taken together, miR-373 functions paradoxically, it
promotes cell growth, cell migration and invasion on
one side, but on the other it yields the opposite effect.
This phenomenon could be explained in an oversimpli-
fied way: because each miRNA could target hundreds of
mRNAs or even DNAs, the ultimate effect of deregula-
tion of one particular miRNA depends on the genetic
characteristic of cancer cells as well as tumor micro-
environment. Considering the heterogeneity of tumor,
it is not hard to comprehend the unpredictable func-
tions of miR-373.
miR-373 and cancers: evidence from both
cultured cancer cell lines and clinical samples
miR-373, either down-regulated or up-regulated, has been
implicated in tumorigenesis of various types of tumors
(Table 2). In addition to chromosomal rearrangements of
19q13.4 that result in overexpression of miR-373 [32],
many upstream factors have been demonstrated to regu-
late the expression of miR-373. Hypoxia can induce the
expression of miR-373 by activating transcription factors
hypoxia inducible factor 1 (HIF-1) [9]. Activation of onco-
genes, such as Myc [33], β-catenin [19], can also up-
regulate miR-373 expression. As for down-regulation of
miR-373, epigenetic silencing is the major reason [16, 23,
27, 35]. Meanwhile, infection of Helicobacter pylori (Hp)
or Hepatitis B virus (HBV) can also inhibit miR-373 ex-
pression [12, 29]. Here, we dissect the functions of miR-
373 from the perspective of specific cancer, highlighting
its differential role in distinct cancer.miR-373 and testicular germ cell tumors (TGCTs)
TGCTs are classified into two histopathological types:
seminomas and non-seminomas. The non-seminomas
comprise of embryonal carcinoma (EC, the stem cell com-
ponent), teratocarcinoma (TC, somatic differentiation),
and yolk sac tumor and choriocarcinoma (YS and CH,
extra-embryonal tissues) [7, 50].
The oncogenic potential of miR-373 was first explored
in TGCTs [7]. In cell lines originating from TGCTs, four
out of seven expressed the miR-371-3 cluster, while in
primary TGCTs tissue, most seminomas (28/32) and
two thirds (14/21) of nonseminomas expressed miR-
372/373. Another study detected the miRNA expression
profiles of seminoma from formalin-fixed and paraffin-
embedded (FFPE) surgical samples, presenting that miR-
373 was up-regulated about 1530 fold in seminoma
compared to normal testicular tissue [51]. Up-regulation
of miR-373, leading to LATS2 suppression, dampens the
p53 pathway which is intact in most TGCTs, and allows
oncogenic mutations to accumulate, playing an essential
role in tumorigenesis of TGCTs.
Unveiling the molecular mechanisms of tumorigenesis
provides us plenty of useful information, facilitating our
discovery of proper diagnostic and prognostic biomarkers
as well as potential therapeutic targets. miRNAs have been
recognized as important biomarkers in the management
of tumors. In particular, circulating cell-free miRNAs,
which exist in a variety of body fluids including blood with
remarkable stability, have received much attention [52]. In
the context of TGCT, serum miR-371-3 have been pro-
posed as advantageous biomarkers for both diagnosis and
follow-up of TGCTs, showing higher sensitivity than con-
ventional biomarkers such as alpha fetal protein (AFP)
and human chorionic gonadotropin (HCG) [53, 54]. How-
ever, more researches remain to be done to validate this
claim.
miR-373 and breast cancer
Breast cancer is a heterogeneous disease comprising four
different subtypes: luminal A, luminal B, basal-like and
human epidermal growth factor receptor 2 (HER2)
positive [55]. These tumors exhibit diverse genetic al-
terations, present distinct gene expression profiles
including miRNA expression profiles [56, 57]. Several
studies have identified the deregulation of miRNAs in
breast cancer, and a variety of miRNAs have been im-
plicated in the regulation of breast cancer initiation
and progression [58]. To date, functions of miR-373 in
breast cancer remain controversial.
Based on results from in vitro and in vivo experi-
ments, miR-373 can both promote and inhibit metasta-
sis of breast cancer cells, functioning in a cell-specific
way. In human breast cancer cell line MCF-7, which is
characterized by non-migratory and non-metastatic
Table 2 Summaries of representative studies investigating the role of miR-373 in clinical samples
Tumor type Sample type miR-373 expression levelsa miR-373 function References
TGCT Primary tumor tissue ↑ oncogene [7, 51]
TGCT serum ↑ oncogene [53, 54]
Breast cancer Primary tumor tissue and metastatic lymph nodes ↑ oncogene [8]
Breast cancer (ER−) Primary tumor tissue ↓ TSG [22]
Breast cancer serum ↑ oncogene [26, 59–61]
HB Primary tumor tissue oncogene [33]
HCC Primary tumor tissue ↑ oncogene [14, 29, 33]
Hilar cholangiocarcinoma Primary tumor tissue ↓ TSG [13, 34, 35]
Gastric cancer Primary tumor tissue ↑ oncogene [20]
Esophageal cancer Primary tumor tissue ↑ oncogene [10]
Colon cancer Primary tumor tissue ↓ TSG [16]
Prostate cancer Primary tumor tissue ↓ Oncogene [11]
Thyroid adenoma Primary tumor tissue ↑ Oncogene [32]
Pancreatic cancer Primary tumor tissue ↓ TSG [31]
Lung cacner Primary tumor tissue ↓ TSG [23]
TGCT testicular germ cell tumor, ER− estrogen receptor negative, TSG tumor suppressor gene, HB hepatoblastoma, HCC hepatocellular carcinoma
a↑represents up-regulation, ↓represents down-regulation
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migration and invasion. In contrast, in human breast
cancer cell line MDA-MB-435, which expresses en-
dogenous miR-373, down-regulation of miR-373 sig-
nificantly weakened cancer cell migration and invasion
[8]. However, in MDA-MB-231, which is an aggressively
invasive ER− breast cancer cell line, overexpression of
miR-520c/373 blunted the invasive capacity of cancer
cells [22].
Could the investigation of clinical samples shed light
on functions of miR-373? The answer remains inconclu-
sive. On one side, miR-373 was demonstrated to be posi-
tively correlated with higher metastatic phenotype [8],
on the other, miR-520c/373 was shown to be negatively
correlated with lymph node metastasis [22]. Both studies
have small sample size, which might be insufficient to
reach a consistent result in such a heterogeneous disease
as breast cancer. Large scales of patient cohorts are
needed to specialize the paradoxical functions of miR-373
in each subtype with different genetic context.
In parallel with the extensive investigations of circulat-
ing cell-free miRNAs as biomarkers, serum or plasma
miR-373 was also explored as a potential biomarker in
breast cancer [26, 59–61]. The expression levels of plasma
miR-373 were found to be significantly higher in breast
cancer patients with lymph node metastasis compared
with those without lymph node metastasis, suggesting that
plasma miR-373 has an ability to discriminate lymph node
status of breast cancer [59]. In addition, serum miR-373
was found to be significantly higher in patients of breast
cancer than healthy women, which indicated that miR-373is a promising diagnostic biomarker. Serum miR-373 ex-
pression levels of HER2-negative breast cancer were
higher than that of HER2-positive patients, showing us
the probability that serum miR-373 might be utilized to
estimate the HER2 status of the primary tumor [60]. Fur-
ther study suggested that serum exosomal miR-373 is the
predominant source of circulating miR-373, the level of
serum exosomal miR-373 was associated with negative ER
and PR status [28]. In HER2-positive patients, however,
serum expression levels of miR-373 did not correlate with
prognosis [61].
Nevertheless, there are visibly limited studies to specu-
late the potential role of miR-373 as a biomarker. Al-
though a single miR-373 could be used as diagnostic and
prognostic biomarker with considerable sensitivity and
specificity, considering the innate heterogeneity of breast
cancer, combination of a panel of relevant miRNAs is
more reasonable and advisable. Therefore, more investi-
gations are warranted.
miR-373 and liver cancer
Since miR-373 was identified as an ESC-specific micro-
RNA, its implication in cancer can be easily connected
to embryonic carcinomas. In addition to TGCTs, the
role of miR-371-3 cluster in hepatoblastomas (HBs), a
rare embryonic neoplasm but a common pediatric liver
cancer derived from liver progenitor cells, was also ex-
plored [33]. In a study conducted by Cairo et al. [33], they
investigated the MYC-driven reprograming of miRNAs in
HBs, identified two relevant miRNA cluster acting in an
opposite way. miR-371-3 was the miRNA cluster that was
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clusters, comprising miR-100, let-7a, miR-371, miR-373,
was identified, which could be used to discriminate not
only aggressive HBs but also invasive HCCs. Up-regulated
miR-373 cooperating with other deregulated miRNAs,
which confers stem cell-like characteristics to cancer cells,
is a biomarker for poor prognosis.
Two other studies investigated the potential roles of
miR-373 in HCCs [14, 29]. They both demonstrated the
up-regulation of miR-373 in tumor tissues compared
with non-tumor tissues. However, mechanism analysis
from different perspectives showed us distinct functions
of miR-373. Wu et al. [14] evidenced that miR-373 func-
tions as an oncogene. By down-regulating PPP6C, miR-
373 facilitates the proliferation of HCC cell lines HepG2
and QGY-7703. Arzumanyan et al. [29] underlined the
impact of HBx in liver cancer, suggested that miR-373
expression levels were down-regulated by HBx in HepG2X
cells and tissue sections from HBV infected patients, and
suppressed expression of miR-373 in liver probably repre-
sents a more aggressive phenotype.
miR-373 and other tumors
In addition to the foregoing mentioned tumors, miR-373
was widely investigated in many other tumors, including
hilar chlangiocarcinoma [13, 34, 35], gastric cancer [20],
esophageal cancer [10], colon cancer [16], prostate can-
cer [11], thyroid adenoma [32], pancreatic cancer [31]
and lung cancer [23, 27] (Table 2).
In principle, miR-373 was considered to function as an
oncogene or a tumor suppressor based on its up-
regulated expression or down-regulated expression in
tumors compared with non-tumor samples. Neverthe-
less, in prostate cancer [11], of which miR-373 expres-
sion levels were down-regulated in both tumor tissues
and cancer cell lines, exogenous miR-373 did not arrest
the growth of tumor but accelerate migration and inva-
sion by impeding CD44 translation, suggesting miR-373
might act as an oncogene unexpectedly.
Conclusion
Initially identified as an ESC-specific miRNA, miR-373
is one of the interested fields in recent years. While
evidences from cancer cell lines suggested its oncogenic
or tumor-suppressive functions, analysis of clinical
tumor samples further confirmed that deregulation of
miR-373 plays a critical role in tumorigenesis. However,
considering the limited numbers of studies available as
well as the bidirectional functions of miR-373 acting in a
cell-specific way, more investigations are warranted. The
following aspects deserve future attention. First, the up-
stream molecular regulators of miR-373, which are
responsible for the altered expression of miR-373, such
as HIF-1 [9], MYC [33] and MBD2 [34], need to beexplored. Second, additional targets of miR-373 urge to
be verified, which may reveal more crosslinks between
miR-373 and classical tumor-related signaling pathways
such as NF-κB, TGF-β [22], Wnt/β-catenin [19] and JAK/
STAT [28]. This would promote us to better understand
its pleiotropic functions in tumorigenesis. At last, with re-
gard to utilize miR-373 as a biomarker either in diagnosis
or prognosis of cancer, studies with large cohorts of pa-
tients are needed, and the combination of a variety of
miRNAs including miR-373 may be more effective.
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